KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68 JPY | -4.23% |
|
-9.33% | -15.00% |
| Sales 2022 | 8 1.24K | Sales 2023 | 39 6.03K | Capitalization | 4.49B 693B |
|---|---|---|---|---|---|
| Net income 2022 | -2.02B -311B | Net income 2023 | -1.49B -230B | EV / Sales 2022 | 293,180,634 x |
| Net cash position 2022 | 3.9B 603B | Net cash position 2023 | 2.62B 406B | EV / Sales 2023 | 47,693,163 x |
| P/E ratio 2022 |
-2.81
x | P/E ratio 2023 |
-2.99
x | Employees | 12 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 76.96% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.23% | ||
| 1 week | -9.33% | ||
| Current month | -11.69% | ||
| 1 month | -15.00% | ||
| 3 months | -10.53% | ||
| 6 months | -13.92% | ||
| Current year | -15.00% |
1 week
67.00
74.00
1 month
67.0083.00
Current year
67.00104.00
1 year
67.00115.00
3 years
67.00322.00
5 years
67.00510.00
10 years
67.007 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ryo Kubota
CEO | Chief Executive Officer | 57 | 15-12-10 |
Hiroki Maekawa
DFI | Director of Finance/CFO | 56 | 18-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shintaro Asako
BRD | Director/Board Member | 49 | 16-02-29 |
Ryo Kubota
CEO | Chief Executive Officer | 57 | 15-12-10 |
Hiroki Maekawa
DFI | Director of Finance/CFO | 56 | 18-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 68 | -4.23% | 358,200 |
| 24-04-18 | 71 | +2.90% | 194,000 |
| 24-04-17 | 69 | -2.82% | 433,600 |
| 24-04-16 | 71 | -2.74% | 378,400 |
| 24-04-15 | 73 | -1.35% | 154,200 |
Delayed Quote Japan Exchange, April 19, 2024 at 02:00 am EDT
More quotes
Kubota Pharmaceutical Holdings Co., Ltd. is a Japan-based company mainly engaged in the operation and management of subsidiaries. Its subsidiaries are mainly engaged in discovering and developing drug candidates to treat and slow the progression of sight-threatening ophthalmic diseases. The Company operates pharmaceutical development segment. It focuses on the development of oral formulation for age-related macular degeneration (AMD), glaucoma and dry eye syndrome.
Sector
Pharmaceuticals
Calendar
2024-05-13
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -15.00% | 25.84M | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- 4596 Stock
